Pharmacy spending (more from Desktop Resource, Feb. 2008)
One of the most important therapeutic classes according is going to be cancer and transplant. "In fact, its contribution to spending increases over the next three years is definitely underestimated here since our projections are based on pharmacy claims data and a large portion of the spending for cancer treatments is paid through the medical benefit," says Lon Castle, MD, senior director, department of medical and analytical affairs at Medco.
One of the most important therapeutic classes according to Figure 2 is going to be cancer and transplant. "In fact, its contribution to spending increases over the next three years is definitely underestimated here since our projections are based on pharmacy claims data and a large portion of the spending for cancer treatments is paid through the medical benefit," says Lon Castle, MD, senior director, department of medical and analytical affairs at Medco. "We estimate that the pharmacy spending in this class is going to increase dramatically."
According to Dr. Castle, in 2006 cancer spending grew nearly 38%, becoming the largest contributor to specialty drug trend. Almost 25% of all specialty drugs approved last year were for cancer. There are more than 500 new cancer drugs and indications for existing cancer drugs under development. These include the more targeted and personalized cancer therapies that are expected to comprise the majority of cancer drugs developed over the next five to seven years.
New Guidance for Managing People With Acute Kidney Injury Requiring Outpatient Dialysis
March 14th 2025Patients with acute kidney injury requiring temporary hemodialysis often follow the protocol used for people on long-term dialysis, despite significant pathophysiological differences between the two.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Where Are They Now? Lissy Hu Joins Ascend to Tackle Workforce Challenges
March 14th 2025Lissy Hu, M.D., MBA, CEO of Ascend Learning, was one of Managed Healthcare Executive’s 2022 Emerging Leaders in Healthcare winners. The editors caught up with Hu as part of our new “Where Are They Now?” series spotlighting the career paths of past emerging leaders.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 14th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
